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Chronic antidepressant administration increases neurotrophin levels in the central and peripheral 
nervous system, leading to an increase of neuronal sprouting, reestablishment of neural networks and 
neurotransmitter levels. Injured peripheral nerves regenerate at very slow rates. However, the recovery of 
the hypogastric nerve in rodents after injury is significantly improved with neurotrophin administration. 
Accordingly, our goal was to determine whether treatment with the antidepressant fluoxetine affects 
catecholamine levels and neuronal function, after surgical denervation of the rat vas deferens. 
Noradrenaline levels in the denervated vas deferens were higher in fluoxetine-treated animals than in the 
vehicle-treated group, as measured by high performance liquid chromatography. In functional studies 
of smooth muscle contraction, the responses induced by phenylephrine or ATP, as well as pre-synaptic 
α2-adrenoceptor reactivity, were not modified by chronic treatment with the antidepressant. However, 
the contraction mediated by neuronal release of noradrenaline induced by tyramine was increased on 
days 7 and 21 after denervation in rats treated with fluoxetine. These data indicate that fluoxetine can 
improve functional recovery after rat vas deferens denervation.
Uniterms: Fluoxetine/chronic administration/effects. Denervation. Antidepressants/long term use/
experimental study. Adrenergic neurotransmission. Noradrenaline/neuronal release.
A administração crônica de antidepressivos aumenta os níveis de neurotrofinas no sistema nervoso 
central, levando a um aumento da arborização neuronal, restabelecendo a rede neural e os níveis de 
neurotransmissores. Lesões do sistema nervoso periférico mostram uma regeneração muito lenta. 
Entretanto, a recuperação após a lesão do nervo hipogástrico em roedores é significativamente melhorada 
após a administração de neurotrofinas. Nesse sentido, nosso objetivo foi verificar se o tratamento com o 
antidepressivo, fluoxetina, interfere nos níveis de catecolaminas e na função neuronal, após a desnervação 
cirúrgica do ducto deferente de rato. Nos vasos deferentes desnervados, os níveis de catecolaminas nos 
grupos tratados com fluoxetina foram maiores que no grupo veículo, quantificados em cromatografia 
líquida de alta eficiência (CLAE). Nos estudos funcionais, a contração da musculatura lisa induzida pela 
fenilefrina ou pelo ATP, assim como a reatividade pré-sináptica α2-adrenérgica, não foram modificadas 
com o tratamento crônico de fluoxetina. Contudo, nas contrações mediadas pela liberação neuronal de 
norepinefrina induzida por tiramina, observou-se aumento da contração nos dias 7 e 21 após a desnevação 
em ratos tratados com fluoxetina. Esses dados indicam que a fluoxetina pode melhorar a recuperação 
funcional do vaso deferente de rato após a desnervação.
Unitermos: Fluoxetina/administração crônica/efeitos. Desnervação. Antidepressivos/uso contínuo/estudo 
experimental. Neurotransmissão adrenérgica. Norepinefrina/liberação neuronal
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INTRODUCTION
Although the primary actions of antidepressants 
are usually related to an increase in monoamine levels in 
the central nervous system (CNS), the exact molecular 
mechanisms by which these agents exert their therapeutic 
effects are not well understood (Slattery, Hudson, Nutt, 
2004). Several indications, such as brain imaging of 
post mortem animals and of depressed human patients 
show a correlation between depression and an axonal 
atrophy or reduction of the neuronal networks in many 
CNS areas (Slattery, Hudson, Nutt, 2004; Nestler et al., 
2002). These neuronal alterations are reversed by chronic 
administration of antidepressants, which also induce 
an increase in axonal sprouting (Carlson et al., 2006; 
Santarelli et al., 2003). Neurotrophins such as nerve 
grow factor (NGF) and brain derivate neurotrophic factor 
(BDNF) regulate neuronal development and cell survival 
in the nervous system (Wang et al., 2008; McAllister, 
Katz, Lo, 1999). Chronic antidepressant administration 
induces an increase in levels of neurotrophic factors 
(Sofroniew, Howe, Mobley, 2001; Castrén, 2005; Kuipers, 
Bramham, 2006) and in the expression and activation of 
BDNF receptors in the hippocampus and frontal cortex of 
rodents (Russo-Neustadt et al., 2000; Balu et al., 2008). 
Chronic fluoxetine treatment (selective serotonin reuptake 
inhibitors) increases NGF levels in cerebral areas, such 
as the prefrontal cortex and hippocampus (Hassanzadeh, 
Hassanzadeh, 2009). Due to the fact that antidepressants 
increase neurotrophin levels in the CNS, it is speculated 
that this process could also occur in the peripheral nervous 
system (PNS), where neuronal regeneration after a lesion 
also depends on neurotrophic factors, mainly NGF. In the 
urogenital tract, which is rich in neurotrophin receptors 
(Keast, Kepper, 2001), chronic treatment with exogenous 
NGF facilitates autonomic nerve regrowth (Burgers et al., 
1991) and induces an increase neuronal activity (Milner 
et al., 1995). The vas deferens is a urogenital organ with 
a high neuronal network density, formed in great part by 
sympathetic nerves (Batra, 1974; Wanigasekara, Kepper, 
Keast, 2003). Therefore, the aim of the present work was 
to determine whether chronic administration of fluoxetine 
increases noradrenaline levels in the denervated vas 
deferens, which could indicate an improvement in the 
functional recovery process after nerve injury.
MATERIAL AND METHODS
Animals and surgical procedures
Male Wistar rats, 5 months old, weighing between 
300-350 g and housed under standard conditions (24 oC 
and a controlled 12-h light/dark cycle), were used. All 
experimental procedures were approved by the Ethics 
Committee of the Federal University of São Paulo.
Surgical denervation of both vasa deferentia was 
performed according to Kasuya and colleagues (1969). 
Briefly, the rats were anesthetized by intraperitoneal 
injection of ketamine/xylazine, and through a suprapubic 
incision, the prostatic portion of the vas deferens was 
exposed. The serous coat of this prostatic region, where 
the deferential artery and the hypogastric plexus come in 
contact with the vas deferens, was carefully picked off 
from approximately 1 cm from the prostatic end. During 
this procedure, great care was taken to avoid injury to 
the vas deferens and the vascular tissue. Later, the vasa 
deferentia were put back in place and the incision was 
sutured. Sham-operated rats (controls for the denervated 
rats) were operated in parallel, under the same conditions 
as the denervated group, with the exception that no 
denervation was performed. The rats were euthanized 
by CO2 asphyxiation 7, 21 and 28 days after the surgery. 
Both vasa deferentia were removed and prepared 
for in vitro contraction experiments or biochemical 
analysis.
Treatment
The rats were treated daily with fluoxetine 
(10 mg/kg i.p.) or vehicle (saline with 1% dimethyl 
sulfoxide) for 11 days prior to surgery and up to 24 h before 
euthanasia.
Contraction experiments (in vitro)
Tissues preparation
The vasa deferentia from denervated or sham-
operated animals, treated with fluoxetine or vehicle, 
were removed for in vitro contraction experiments. 
Whole organs were acclimated in 10-mL chamber organ 
baths, containing a nutrient solution (138 mM NaCl; 
5.7 mM KCl; 1.8 mM CaCl2; 15.0 mM NaHCO3; 
0.36 mM NaHPO4; 5.5 mM dextrose) prepared in 
glass-distilled deionized water at 30 °C and constant 
aeration (95% O2 and 5% CO2). Isometric contractions 
of the smooth muscle were recorded on a physiograph 
(UGO-BASILE® MOD.7080) using an isometric 
transducer (UGO-BASILE® MOD.7006) under a resting 
tension of 1.0 g. After a period of stabilization (30 min), 
the vas deferens was contracted by a single concentration 
of barium chloride (0.01 M) to test the viability of the 
tissue. After achieving the maximal contraction, the tissue 
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was washed out and the experimental protocols were 
started 30 min later.
Contractile response to the indirect adrenergic agonist, 
tyramine
The vas deferens was contracted by a single 
concentration of the indirect adrenergic agonist tyramine 
(100 µM) until the maximal contraction was achieved.
Contractile response to electrical stimulation (ES)
The vas deferens was placed between two parallel 
platinum electrodes and an electrical field stimulation was 
performed with a Grass®S88 stimulator (50 V supramaximal 
voltage, 3 ms duration, 10 Hz frequency). These electrical 
stimulation parameters induce only neuronal stimulation 
without direct muscle stimulation, since this contraction 
was inhibited by tetrodotoxin, as previously described in our 
laboratory (Santos et al., 2003). Only the phasic component 
of the contraction was considered.
Analysis of pre-synaptic α2-adrenoceptor activity
The vas deferens was electrically stimulated with 
a frequency of 0.05 Hz (50 V, 3 ms). When the electrical 
twitch responses were stabilized, concentration-response 
curves were obtained for the α2-adrenoceptor agonist 
clonidine. The pIC50 parameter (negative logarithm of the 
concentration of clonidine that induces a 50% inhibitory 
effect) was obtained.
Analysis of post-synaptic reactivity
Three cumulative concentration-response curves for 
the α1-adrenergic agonist phenylephrine were obtained 
at 30-min intervals. Afterwards, the contraction induced 
by a single concentration of ATP (10 mM) was recorded. 
The parameters obtained were maximum effect (Emax, 
in grams of tension) and pD2 (negative logarithm of the 
concentration of the agonist that produces 50% of the 
maximum effect) for phenylephrine.
Biochemical analysis of noradrenaline content
The vasa deferentia from denervated or sham-
operated animals treated with fluoxetine or vehicle 
were removed for biochemical analysis to determine the 
noradrenaline content of the tissue (Conceição et al., 
2005). Briefly, the vasa deferentia were homogenized 
in 0.4 N perchloric acid, containing 0.1% sodium 
metabisulfite. After centrifugation (7000 x g, 45 min, 4 °C), 
the supernatant was aspirated and stored at -80 °C until 
analyzed by high-performance liquid chromatography 
(HPLC) with electrochemical detection.
Statistical analyses 
The results were expressed as the mean ± standard 
error. The significance of differences between two means 
was evaluated using a two-tailed Student t-test. Treatment 
groups were compared using one-way analysis of variance 
(ANOVA) and a post-hoc analysis of differing groups was 
carried out using a Tukey-Kramer test. P less than 0.05 
indicated a statistically significant deference between 
groups.
Drugs
Chemicals: adenosine 5’-triphosphate (ATP), 
clonidine hydrochloride, norepinephrine (L-arterenol 
bitartrate) and tyramine were from Sigma Chemical 
Co., USA; fluoxetine, from Farmasa, BR; phenylephrine 
(L-phenyl-ephrine hydrochloride) from RBI, USA; and 
barium chloride, from Merck, BR. Stock solutions of the 
drugs were prepared in distilled water, with the exception 
of norepinephrine and phenylephrine, which were 
dissolved in 0.01 N HCl. Fluoxetine was dissolved in 1% 
DMSO in deionized water.
RESULTS
Influence of chronic fluoxetine treatment on the 
denervation and reinnervation profile of rat vas 
deferens
The characterization of the denervation and 
reinnervation of rat vas deferens was obtained indirectly, 
using in vitro contraction experiments, or directly, by 
biochemical noradrenaline quantification.
In vitro contraction experiments
Neuronal viability and pre-synaptic and post-
synaptic receptor reactivity were analyzed in sham-
operated and denervated vas deferens obtained from 
rats chronically treated for 11 days prior to surgery, 
with fluoxetine (10 mg/kg/day) or vehicle. The in vitro 
contraction experiments were done on days 7, 21, and 
28 after surgery. Neuronal viability was measured under 
conditions that promote neurotransmitter release, as 
contraction induced by the indirect adrenergic agonist 
tyramine or by electrical stimulation.
Tyramine
Figure 1a shows that the amplitude of the contraction 
induced by tyramine (100 μM) was lower in all denervated 
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groups, compared to the respective sham-operated groups, 
as expected. The lowest contraction was observed on day 
7, followed by a gradual and partial recovery of response 
through day 28. Considering the denervated groups, in 
the fluoxetine-treated denervated group, the amplitude 
of the contraction was greater than that of its respective 
vehicle-treated denervated group. Differences in the 
amplitude of contraction were significant on days 7 and 
day 21. No differences were noted in the amplitude of 
contraction in either the fluoxetine-treated or vehicle-
treated sham-operated groups. These results indicate that 
fluoxetine treatment can improve the contraction induced 
by tyramine in denervated vas deferens.
Electrically evoked contractions
The amplitude of the contraction induced by 
electrical field stimulation (10 Hz) in all groups is 
shown in Figure 1b. As observed with tyramine, in the 
denervated groups, the amplitude of the contraction 
was reduced at all time points tested compared to the 
respective sham-operated groups. The lowest contraction 
was observed on day 7, followed by a partial recovery 
of response through day 28. In the fluoxetine-treated 
group, there was a tendency towards an increase in the 
amplitude of contraction, but no statistical differences 
were obtained when compared to the respective vehicle-
treated denervated group. In sham-operated groups, no 
differences were noted between the fluoxetine-treated and 
vehicle-treated groups.
Post-synaptic and pre-synaptic receptor reactivity
The increase in tyramine-induced contraction 
observed in the denervated groups after fluoxetine treatment 
could be due to an alteration, induced by fluoxetine, in 
the post-synaptic reactivity of the vas deferens. The post-
synaptic reactivity of the tissue was studied using exogenous 
agonists to evaluate the adrenergic and purinergic 
component of contraction. After denervation, an expected 
super-sensitivity of the vas deferens to the α1-adrenergic 
agonist phenylephrine was observed, characterized by an 
increase in the Emax (in the day 7 and day 28 groups) and 
by the leftward shift of the concentration-response curves 
(increase in pD2 value) compared to the respective sham-
operated group (Table I). Chronic fluoxetine treatment did 
not induce any alteration in these parameters in either the 
sham or denervated group, when compared to the respective 
vehicle-treated group (Table I).
After denervation, an increase in the amplitude 
of exogenously applied ATP (100 μM) was observed 
in some groups; however, fluoxetine treatment did not 
induce any differences in the responses when compared 
to the respective vehicle-treated group (Table II). 
The pre-synaptic α2-adrenoceptor reactivity was also 
analyzed. The α2-adrenoceptor reactivity was evaluated 
by means of an inhibitory concentration-response curve 
to the α2-adrenoceptor agonist clonidine over the twitch 
contractions induced by electrical stimulation (0.05 Hz) 
in sham-operated vas deferens. No differences were noted 
in pIC50 value between the vehicle- (9.09±0.10, 8.89±0.07, 
8.77±0.18) and fluoxetine-treated (8.96±0.07, 8.97±0.03, 
8.74±0.04) groups at all time points tested (respectively 
7, 21 and 28 days).
Noradrenaline quantification
Noradrenaline levels in rat vas deferens were 
measured by HPLC with electrochemical detection 
FIGURE 1. Histogram showing the maximum effect induced 
by (a) a single concentration of tyramine (100 µM) and (b) 
electrical stimulation (3 ms, 50 V, 10 Hz, phasic response) in 
rat vas deferens. The data are plotted for the sham-operated 
animals treated with vehicle (white), sham-operated animals 
treated with fluoxetine (dark gray), denervated animals treated 
with vehicle (light gray) and denervated animals treated with 
fluoxetine (black) for 7, 21 or 28 days after surgery. The bars 
represent the mean ± S.E.M from four to six experiments. ¤, 
indicates a significant difference in relation to respective vehicle 
control group (P<0.05); *, indicates a significant difference 
in relation to the respective sham-operated group (P<0.05); #, 
indicates a significant difference in relation to the respective 
day 7 group (P<0.05)
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in sham-operated and denervated groups treated with 
fluoxetine or vehicle. Figure 2 shows that denervation 
caused a drastic decrease in noradrenaline levels, 
which was observed in both the treated and untreated 
groups, reaching the lowest concentration seven days 
after denervation, followed by a gradual recovery on 
days 21 and 28. Considering the denervated groups, 
noradrenaline levels were higher in the fluoxetine-
treated group compared to the vehicle-treated group, 
at all time points studied. In the sham-operated group, 
noradrenaline levels were not altered by treatment with 
fluoxetine.
DISCUSSION
The main finding of the present study was that 
neurotransmitter levels were higher in denervated vas 
TABLE I - pD2 and maximum amplitude of contraction (Emax) in grams of tension from the phenylephrine concentration response-
curves obtained in vas deferens from sham-operated and denervated rats treated with vehicle or fluoxetine for 7, 21 and 28 days. 
Each value represents the mean ± standard error from 9 to 12 experiments
Phenylephrine
pD2
7 days 21 days 28 days
sham-operated
vehicle 6.78±0.08 6.49±0.15 6.56±0.05
fluoxetine 6.73±0.09 6.65±0.12 6.66±0.07
denervated
vehicle 7.16±0.08* 7.28±0.13* 7.21±0.16*
fluoxetine 7.09±0.08* 7.14±0.08* 7.06±0.12*
Emax (g)
sham-operated
vehicle 1.80±0.19 2.21±0.22 1.85±0.10
fluoxetine 2.23±0.19 2.27±0.15 2.06±0.16
denervated
vehicle 3.28±0.40* 2.32±0.29 2.47±0.27*
fluoxetine 3.13±0.20 2.57±0.17 2.75±0.14
* indicates a significant difference in relation to the sham-operated group (P<0.05).
TABLE II - Maximum amplitude of contraction (Emax), in grams of tension, from a single concentration of ATP (100 µM) obtained in 
vas deferens from sham-operated and denervated rats treated with vehicle or fluoxetine for 7, 21 and 28 days. Each value represents 
the mean ± standard error of 5 to 8 experiments
ATP (100 µM)
Emax
7 days 21 days 28 days
sham-operated
vehicle 1.08±0.08 1.30±0.21 0.90±0.11
fluoxetine 1.35±0.23 1.08±0.12 1.23±0.13
denervated
vehicle 1.68±0.16* 1.77±0.26 1.61±0.26*
fluoxetine 1.82±0.18 1.64±0.16* 1.54±0.17
* indicates a significant difference in relation to the sham-operated group (P<0.05).
deferens from rats chronically treated with fluoxetine 
compared to denervated vehicle-treated duct. These 
results indicate that fluoxetine treatment could improve 
the process of reinnervation that normally occurs after vas 
deferens denervation.
Tissue neurotransmitter levels were evaluated by 
direct determination of tissue noradrenaline levels using 
electrochemical detection and indirect measurement 
by analyzing contractions induced by the indirect 
adrenergic agonist tyramine or by electrical stimulation. 
We observed that denervated vas deferens from animals 
treated with fluoxetine had an amplitude of contraction 
induced by tyramine that was greater than that observed 
in vehicle-treated denervated animals. Although this 
increase in tyramine contraction could indicate an 
increase in noradrenaline release, it could also be due 
to fluoxetine-induced modification of the reactivity 
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of post-synaptic receptors or changes in the feedback 
mechanisms mediated by pre-synaptic receptors. 
However, control experiments with the α1-adrenergic 
agonist phenylephrine, purinergic agonist ATP and 
the α2-adrenergic agonist clonidine showed that the 
reactivity of the receptors associated with these agonists 
was not modified by fluoxetine treatment. As a result, the 
increase in tyramine-induced contraction could be due to 
a greater availability of noradrenaline. This hypothesis 
was confirmed by results obtained with electrochemical 
quantification of noradrenaline levels, where higher 
noradrenaline levels were observed in fluoxetine-treated 
denervated group compared to the vehicle-treated 
denervated group. In contrast, contractions induced 
indirectly by electrical stimulation were not significantly 
different, when comparing these two groups, although 
a tendency towards an increase in the amplitude of 
contraction was observed. The capacity of fluoxetine 
to increase neurotransmitter levels or neurotransmitter 
release in the experiments with tyramine and in the 
noradrenaline quantification was very slight, at the 
threshold of statistical validation. Therefore, one could 
argue that in the electrical stimulation studies, this 
weak fluoxetine action was not sufficient to induce a 
statistically significant effect. One possible explanation 
of this low effect of fluoxetine is the treatment protocol 
(dose and treatment duration). This protocol was based 
on published data in the literature. In CNS studies, 
chronic fluoxetine treatment (10 mg/kg/day, 21 days) 
induces an increase in NGF and BDNF levels in several 
brain regions (Molteni et al., 2006; Hassanzadeh, 
Hassanzadeh, 2009). Although the protocol used in our 
experiments followed one used to obtain effects in the 
CNS, this protocol may not be adequate for studies in the 
PNS. Another possibility is that the mechanism involved 
in the antidepressant-induced increase in neuronal 
viability is not as efficient in PNS as in CNS.
At the moment, it is not possible to determine the 
mechanism involved in this increase in noradrenaline 
levels in fluoxetine-treated denervated vas deferens. 
Several lines of evidence suggest that in the CNS the 
antidepressant-induced increase in neuronal viability is 
mediated by different signaling pathways, specifically 
through the activation of the transcriptional factor CREB 
and an increase in the synthesis of neurotrophic factors 
(Nibuya, Nestler, Duman, 1996; Altar, 1999). In the 
PNS, the antidepressant effects on neurotrophin levels 
are not well studied. Because the urogenital tract (and the 
vas deferens) is rich in NGF and neurotrophin receptors 
(Keast, Kepper, 2001), the effect of fluoxetine treatment 
could be mediated by the synthesis of NGF. Of note, 
the fluoxetine effects were obtained only in denervated 
vas deferens. Fluoxetine treatment did not affect sham-
operated groups. These data indicate that fluoxetine 
can only increase noradrenaline levels during neuronal 
regeneration, thus suggesting that this effect occurs mainly 
in situations where the process of regeneration after a 
lesion has already been initiated.
In summary, our results indicate that chronic 
fluoxetine treatment could change plasticity during 
peripheral neuron regeneration, increasing catecholamine 
levels after denervation, where this could highlight a new 
potential therapeutic benefit of antidepressants.
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